Microsoft’s AI for Better Health aims to transform health and life sciences by combining trusted data, responsible AI, and human expertise to accelerate decision-making and improve patient outcomes across discovery, development, manufacturing, and delivery.

Today's AI value comes from transforming entire workflows, ensuring data readiness and governance, and embedding AI across the full value chain rather than relying on isolated copilots.

AI is expanding people-facing impact and experiences, with tools like CustomerInsights.AI delivering high-accuracy calculations and efficiency gains, Hanmi using Copilot for field teams, and Pierre Fabre deploying PLA.I.GROUND to scale AI-powered support for employees and patients.

Resilient operations hinge on unified platforms and data to improve visibility and agility in supply chains and manufacturing, with Rohto Pharmaceutical and Astellas illustrating integrated platforms and large-scale cloud migrations that enable AI-driven planning and forecasting.

Production acceleration is evident as companies modernize finance and manufacturing with Dynamics 365 and Power BI, and as Kӧrber uses Azure OpenAI and Foundry to shorten recipe-management timelines and digitize manufacturing processes.

Pharmaceutical AI adoption is moving from isolated experiments to integrated workflows across R&D, manufacturing, and operations to bring therapies to patients faster and more efficiently.

Leaders are achieving measurable impact by embedding AI into scientifically critical workflows, governance, and human oversight, enabling enterprise-scale transformation that accelerates innovation and patient outcomes.

In R&D, AI broadens the set of decisions researchers can evaluate by speeding access to evidence and hypotheses, with platforms like Microsoft Discovery and customer stories from Novo Nordisk, Amgen, Almirall, and UCB shortening time to insight and expanding exploration.